Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Annals of the Rheumatic Diseases

Op0137 Challenging the Difficult-to-Treat Rheumatoid Arthritis: Comparative Analysis of Clinical Efficacy and Drug Retention of Subsequent Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs

View Full Paper
Ask AI
Bookmark
Share

Authors

LŠLadislav ŠenoltCharles UniversityJZJakub ZávadaCharles UniversityKKK. Kusalová

Discussion

Loading...

Member takes

Implication

Cohort study reveals highest drug retention with rituximab in difficult-to-treat rheumatoid arthritis, highlighting effective subsequent biologic and targeted synthetic treatment options.

Key Points

  • Subsequent treatment with rituximab, janus kinase inhibitors, or IL-6Ri achieved disease remission or low activity in over half of difficult-to-treat rheumatoid arthritis cases.
  • Twelve-month drug retention reached 90.1 percent for rituximab compared to 58.8 percent for tumor necrosis factor inhibitors, demonstrating marked differences across drug classes.
  • Analysis of 642 registry patients using the Kaplan-Meier method and simplified disease activity index demonstrates sustained clinical benefit despite previous treatment failures.

Cite This Study

Šenolt et al. (2024) studied this question.

synapsesocial.com/papers/68e6706cb6db6435875fb2f1https://doi.org/10.1136/annrheumdis-2024-eular.5851
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1POS0671 PROFILE AND MANAGEMENT OF D2T-RA PATIENTS IN THE ITALIAN GISEA REGISTRY2024
  2. 2POS0478 SURVIVALTO b/tsDMARDs IN PATIENTS AFTER FULFILLING DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS CLASSIFICATION2024
  3. 3OP0201 REASONS FOR TREATMENT FAILURE: A COMPARISON BETWEEN “MULTI-REFRACTORY” AND “DIFFICULT-TO-TREAT” RHEUMATOID ARTHRITIS PATIENTS2024
  4. 4POS0479 ANALYSIS OF TEMPORAL TRAJECTORIES AND DEFINITION CRITERIA SUSTAINING PERSISTENCE OF THE DIFFICULT-TO-TREAT STATUS OF RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A SINGLE-CENTER, REAL-LIFE STUDY2024
  5. 5OP0118 BASELINE AND PRE-BIOLOGIC PREDICTORS OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS WITH RECENT ONSET DISEASE2024 · 1 citations